Pathfinder Cell Therapy, Inc. – OTC:PFND
Pathfinder Cell Therapy stock price today
Pathfinder Cell Therapy stock price monthly change
Pathfinder Cell Therapy stock price quarterly change
Pathfinder Cell Therapy stock price yearly change
Pathfinder Cell Therapy key metrics
Market Cap | 2.00M |
Enterprise value | 5.40M |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | -5.86 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | -772K |
Income | -1.38M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePathfinder Cell Therapy stock price history
Pathfinder Cell Therapy stock forecast
Pathfinder Cell Therapy financial statements
| Dec 2014 | 0 | -368K | |
|---|---|---|---|
| Mar 2015 | 0 | -348K | |
| Jun 2015 | 0 | -300K | |
| Sep 2015 | 0 | -369K |
| Dec 2014 | 106000 | 6.04M | 5706.6% |
|---|---|---|---|
| Mar 2015 | 86000 | 6.30M | 7331.4% |
| Jun 2015 | 49000 | 6.49M | 13244.9% |
| Sep 2015 | 39000 | 6.76M | 17356.41% |
| Dec 2014 | -127K | 0 | 130K |
|---|---|---|---|
| Mar 2015 | -176K | 0 | 171K |
| Jun 2015 | -98K | 0 | 77K |
| Sep 2015 | -178K | 0 | 182K |
Pathfinder Cell Therapy alternative data
| Aug 2023 | 1 |
|---|---|
| Sep 2023 | 1 |
| Oct 2023 | 1 |
| Nov 2023 | 1 |
| Dec 2023 | 1 |
| Jan 2024 | 1 |
| Feb 2024 | 1 |
| Mar 2024 | 1 |
| Apr 2024 | 1 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Pathfinder Cell Therapy other data
-
What's the price of Pathfinder Cell Therapy stock today?
One share of Pathfinder Cell Therapy stock can currently be purchased for approximately $0.
-
When is Pathfinder Cell Therapy's next earnings date?
Unfortunately, Pathfinder Cell Therapy's (PFND) next earnings date is currently unknown.
-
Does Pathfinder Cell Therapy pay dividends?
No, Pathfinder Cell Therapy does not pay dividends.
-
How much money does Pathfinder Cell Therapy make?
Pathfinder Cell Therapy has a market capitalization of 2.00M.
-
What is Pathfinder Cell Therapy's stock symbol?
Pathfinder Cell Therapy, Inc. is traded on the OTC under the ticker symbol "PFND".
-
What is Pathfinder Cell Therapy's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pathfinder Cell Therapy?
Shares of Pathfinder Cell Therapy can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Pathfinder Cell Therapy have?
As Jul 2024, Pathfinder Cell Therapy employs 1 workers.
-
When Pathfinder Cell Therapy went public?
Pathfinder Cell Therapy, Inc. is publicly traded company for more then 25 years since IPO on 3 Jan 2000.
-
What is Pathfinder Cell Therapy's official website?
The official website for Pathfinder Cell Therapy is pathfindercelltherapy.com.
-
Where are Pathfinder Cell Therapy's headquarters?
Pathfinder Cell Therapy is headquartered at 12 Bow Street, Cambridge, MA.
-
How can i contact Pathfinder Cell Therapy?
Pathfinder Cell Therapy's mailing address is 12 Bow Street, Cambridge, MA and company can be reached via phone at +61 72450289.
Pathfinder Cell Therapy company profile:
Pathfinder Cell Therapy, Inc.
pathfindercelltherapy.comOTC
1
Biotechnology
Healthcare
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02138
:
ISIN: US70319A1060
:
